Systane Partners with Toronto Blue Jays to Raise Dry Eye Awareness
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 07 2026
0mins
Should l Buy ALC?
Source: Newsfilter
- Partnership Announcement: Systane has partnered with the Toronto Blue Jays as the official eye drop, aiming to raise awareness among the estimated 8.5 million Canadians affected by dry eye, helping them stay comfortable while watching games.
- Symptom Recognition: This partnership seeks to educate fans on recognizing dry eye symptoms such as stinging, burning, and fatigue, thereby enhancing their viewing experience and ensuring they enjoy every memorable moment of the season.
- National Awareness Campaign: The collaboration will leverage stadium activations, digital experiences, and national initiatives to bring dry eye awareness to millions of Canadian fans, increasing public focus on this condition.
- Brand Trust: As the #1 doctor and pharmacist-recommended brand in the dry eye category in Canada, Systane's products are designed to provide effective relief from dry eye symptoms, ensuring fans maintain visual comfort during games.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALC
Wall Street analysts forecast ALC stock price to rise
13 Analyst Rating
7 Buy
5 Hold
1 Sell
Moderate Buy
Current: 79.550
Low
78.17
Averages
93.73
High
117.26
Current: 79.550
Low
78.17
Averages
93.73
High
117.26
About ALC
Alcon AG is a Switzerland-based eye care company. The Company research, develop, manufacture, distribute and sell a full suite of eye care products within two key businesses: Surgical and Vision Care. The Company’s Surgical business is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end needs of the ophthalmic surgeon. The Company’s Vision Care business comprises of daily disposable, reusable and color-enhancing contact lenses and a portfolio of ocular health products, including products for dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The Company operates in 60 countries and serves consumers and patients in over 140 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Systane Partners with Toronto Blue Jays to Raise Dry Eye Awareness
- Partnership Announcement: Systane has partnered with the Toronto Blue Jays as the official eye drop, aiming to raise awareness among the estimated 8.5 million Canadians affected by dry eye, helping them stay comfortable while watching games.
- Symptom Recognition: This partnership seeks to educate fans on recognizing dry eye symptoms such as stinging, burning, and fatigue, thereby enhancing their viewing experience and ensuring they enjoy every memorable moment of the season.
- National Awareness Campaign: The collaboration will leverage stadium activations, digital experiences, and national initiatives to bring dry eye awareness to millions of Canadian fans, increasing public focus on this condition.
- Brand Trust: As the #1 doctor and pharmacist-recommended brand in the dry eye category in Canada, Systane's products are designed to provide effective relief from dry eye symptoms, ensuring fans maintain visual comfort during games.
See More
Alcon to Hold 2026 Annual General Meeting
- AGM Announcement: Alcon is set to hold its fourth Annual General Meeting on April 30, 2026, inviting shareholders to participate in person, which aims to enhance direct communication with shareholders and improve corporate transparency and trust.
- Board Nomination: The Board proposes the election of R. Scott Herren as a new independent director, who brings 35 years of experience as CFO of Cisco Systems, expected to enhance the Board's financial planning and strategic capabilities significantly.
- Dividend Proposal: The Board has proposed a cash dividend of CHF 0.28 per share, which, if approved by shareholders, is expected to be paid on May 7, 2026, providing stable returns to shareholders and boosting investor confidence.
- Financial Review: Shareholders will review Alcon's financial statements and operational review for 2025, ensuring financial transparency and fostering shareholder trust and support for the company's future growth.
See More
Lensar Terminates Merger Agreement with Alcon Amid Regulatory Challenges
- Merger Agreement Termination: Lensar announced the termination of its merger agreement with Alcon due to regulatory challenges, while retaining a $10 million deposit, reflecting a cautious approach towards future transactions.
- Significant Stock Drop: Following the termination of the merger agreement, Lensar's shares plummeted 24% in after-hours trading, indicating a strong market reaction to the failed deal that could impact the company's future financing capabilities.
- Regulatory Review Delays: The transaction originally planned for March 2025 between Lensar and Alcon has been postponed due to opposition from the Federal Trade Commission, with completion now expected in the first half of 2026, increasing uncertainty around the deal.
- Market Sentiment Analysis: Despite LNSR stock dropping 34% over the past 12 months, retail investor sentiment on Stocktwits remains 'bullish', while ALC sentiment is 'neutral', suggesting ongoing confidence in Lensar's future prospects.
See More
Alcon Terminates Merger Agreement with LENSAR
- Merger Termination: Alcon has announced the termination of its merger agreement with LENSAR, believing that the acquisition would have significantly enhanced FLACS innovation and competition; however, the delay and associated costs have rendered the transaction unattractive.
- Regulatory Challenges: The delay in the transaction is closely tied to opposition from the Federal Trade Commission, highlighting significant challenges faced by the healthcare industry in mergers and acquisitions under the current regulatory environment, which may impact future M&A strategies.
- Continued Commitment: Alcon's CEO, David J. Endicott, reaffirmed the company's commitment to advancing cataract surgery through innovative technologies that improve efficiency for surgeons and outcomes for patients, indicating a long-term strategic direction in the eye care sector.
- Market Impact: The termination of this merger may have a short-term negative impact on Alcon's market performance, but it also provides an opportunity for the company to focus resources on other innovative projects, potentially enhancing its competitive position in the future.
See More
Lensar and Alcon Terminate Merger Agreement
- Merger Agreement Termination: Lensar and Alcon have agreed to terminate their planned merger due to anticipated opposition from the Federal Trade Commission, highlighting the regulatory challenges facing industry consolidation.
- Deposit Retention: Lensar will retain the $10 million deposit stipulated in the merger agreement, which somewhat alleviates the financial burden resulting from the failed transaction.
- Market Commitment: Lensar's CEO Nick Curtis expressed disappointment over the merger's outcome but reaffirmed the company's commitment to advancing cataract surgery through its ALLY Robotic Cataract Laser System, indicating confidence in market growth.
- Historical Context: Alcon had previously agreed to acquire Lensar for $14 per share last March, and the termination of this deal reflects a cautious sentiment in the medical device sector regarding mergers, potentially impacting future investor confidence.
See More
Goldman Sachs Analysts Warn of Market Risks
- Market Risk Warning: Goldman Sachs strategist Peter Oppenheimer highlights that current equity market risk premia have fallen to levels not seen since the lead-up to the 2008 financial crisis, indicating a need for caution despite improved market sentiment.
- AIG Financial Performance: American International Group (AIG) reported net premiums of $23.9 billion in 2024 and $23.8 billion in 2025, with a 48% year-over-year increase in general insurance underwriting income in Q4 2025, showcasing strong earnings growth potential.
- AIG Shareholder Returns: AIG returned $6.8 billion to shareholders over the past year, with $5.8 billion in share repurchases and $1 billion in dividends, demonstrating the company's capital management flexibility and commitment to shareholder value.
- Alcon Growth Outlook: Alcon achieved $2.7 billion in sales in Q4 2025, a 9% year-over-year increase, slightly below estimates, yet analysts remain optimistic about future growth, projecting a 27% increase in share price by 2027.
See More
Systane Partners with Toronto Blue Jays to Raise Dry Eye Awareness
- Partnership Announcement: Systane has partnered with the Toronto Blue Jays as the official eye drop, aiming to raise awareness among the estimated 8.5 million Canadians affected by dry eye, helping them stay comfortable while watching games.
- Symptom Recognition: This partnership seeks to educate fans on recognizing dry eye symptoms such as stinging, burning, and fatigue, thereby enhancing their viewing experience and ensuring they enjoy every memorable moment of the season.
- National Awareness Campaign: The collaboration will leverage stadium activations, digital experiences, and national initiatives to bring dry eye awareness to millions of Canadian fans, increasing public focus on this condition.
- Brand Trust: As the #1 doctor and pharmacist-recommended brand in the dry eye category in Canada, Systane's products are designed to provide effective relief from dry eye symptoms, ensuring fans maintain visual comfort during games.
See More
Alcon to Hold 2026 Annual General Meeting
- AGM Announcement: Alcon is set to hold its fourth Annual General Meeting on April 30, 2026, inviting shareholders to participate in person, which aims to enhance direct communication with shareholders and improve corporate transparency and trust.
- Board Nomination: The Board proposes the election of R. Scott Herren as a new independent director, who brings 35 years of experience as CFO of Cisco Systems, expected to enhance the Board's financial planning and strategic capabilities significantly.
- Dividend Proposal: The Board has proposed a cash dividend of CHF 0.28 per share, which, if approved by shareholders, is expected to be paid on May 7, 2026, providing stable returns to shareholders and boosting investor confidence.
- Financial Review: Shareholders will review Alcon's financial statements and operational review for 2025, ensuring financial transparency and fostering shareholder trust and support for the company's future growth.
See More
Lensar Terminates Merger Agreement with Alcon Amid Regulatory Challenges
- Merger Agreement Termination: Lensar announced the termination of its merger agreement with Alcon due to regulatory challenges, while retaining a $10 million deposit, reflecting a cautious approach towards future transactions.
- Significant Stock Drop: Following the termination of the merger agreement, Lensar's shares plummeted 24% in after-hours trading, indicating a strong market reaction to the failed deal that could impact the company's future financing capabilities.
- Regulatory Review Delays: The transaction originally planned for March 2025 between Lensar and Alcon has been postponed due to opposition from the Federal Trade Commission, with completion now expected in the first half of 2026, increasing uncertainty around the deal.
- Market Sentiment Analysis: Despite LNSR stock dropping 34% over the past 12 months, retail investor sentiment on Stocktwits remains 'bullish', while ALC sentiment is 'neutral', suggesting ongoing confidence in Lensar's future prospects.
See More
Alcon Terminates Merger Agreement with LENSAR
- Merger Termination: Alcon has announced the termination of its merger agreement with LENSAR, believing that the acquisition would have significantly enhanced FLACS innovation and competition; however, the delay and associated costs have rendered the transaction unattractive.
- Regulatory Challenges: The delay in the transaction is closely tied to opposition from the Federal Trade Commission, highlighting significant challenges faced by the healthcare industry in mergers and acquisitions under the current regulatory environment, which may impact future M&A strategies.
- Continued Commitment: Alcon's CEO, David J. Endicott, reaffirmed the company's commitment to advancing cataract surgery through innovative technologies that improve efficiency for surgeons and outcomes for patients, indicating a long-term strategic direction in the eye care sector.
- Market Impact: The termination of this merger may have a short-term negative impact on Alcon's market performance, but it also provides an opportunity for the company to focus resources on other innovative projects, potentially enhancing its competitive position in the future.
See More
Lensar and Alcon Terminate Merger Agreement
- Merger Agreement Termination: Lensar and Alcon have agreed to terminate their planned merger due to anticipated opposition from the Federal Trade Commission, highlighting the regulatory challenges facing industry consolidation.
- Deposit Retention: Lensar will retain the $10 million deposit stipulated in the merger agreement, which somewhat alleviates the financial burden resulting from the failed transaction.
- Market Commitment: Lensar's CEO Nick Curtis expressed disappointment over the merger's outcome but reaffirmed the company's commitment to advancing cataract surgery through its ALLY Robotic Cataract Laser System, indicating confidence in market growth.
- Historical Context: Alcon had previously agreed to acquire Lensar for $14 per share last March, and the termination of this deal reflects a cautious sentiment in the medical device sector regarding mergers, potentially impacting future investor confidence.
See More
Goldman Sachs Analysts Warn of Market Risks
- Market Risk Warning: Goldman Sachs strategist Peter Oppenheimer highlights that current equity market risk premia have fallen to levels not seen since the lead-up to the 2008 financial crisis, indicating a need for caution despite improved market sentiment.
- AIG Financial Performance: American International Group (AIG) reported net premiums of $23.9 billion in 2024 and $23.8 billion in 2025, with a 48% year-over-year increase in general insurance underwriting income in Q4 2025, showcasing strong earnings growth potential.
- AIG Shareholder Returns: AIG returned $6.8 billion to shareholders over the past year, with $5.8 billion in share repurchases and $1 billion in dividends, demonstrating the company's capital management flexibility and commitment to shareholder value.
- Alcon Growth Outlook: Alcon achieved $2.7 billion in sales in Q4 2025, a 9% year-over-year increase, slightly below estimates, yet analysts remain optimistic about future growth, projecting a 27% increase in share price by 2027.
See More
